Literature DB >> 10690754

Genetic variation of the human mu-opioid receptor and susceptibility to idiopathic absence epilepsy.

T Sander1, W Berlin, N Gscheidel, B Wendel, D Janz, M R Hoehe.   

Abstract

Pharmacological and autoradiological studies suggest that mu-opioid receptor (OPRM) mediated neurotransmission is involved in the generation of absence seizures. Mutation screening of the human OPRM gene identified a common amino acid substitution polymorphism (Asn40Asp) that differentially modulates the binding affinity of beta-endorphin and signal transduction of the receptor. The present association study tested the candidate gene hypothesis that the Asn40Asp substitution polymorphism in the N-terminal OPRM domain confers genetic susceptibility to idiopathic absence epilepsy (IAE). The genotypes of the Asn40Asp polymorphism were assessed by allele-specific polymerase chain reaction in 72 German IAE patients and in 340 ethnically matched control subjects. The frequency of the Asp40 allele was significantly increased in the IAE patients [f(Asp40) = 0.139] compared to the controls [f(Asp40) = 0.078; chi2 = 5.467, df = 1, P = 0.019; OR = 2.03; 95%-CI: 1.12-3.68]. This allelic association suggests that the functional Asp40 variant of OPRM modulates neuronal excitability underlying the epileptogenesis of IAE.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10690754     DOI: 10.1016/s0920-1211(99)00109-6

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  7 in total

Review 1.  Genetic variations in human G protein-coupled receptors: implications for drug therapy.

Authors:  W Sadee; E Hoeg; J Lucas; D Wang
Journal:  AAPS PharmSci       Date:  2001

2.  A rapid screening method for a single nucleotide polymorphism (SNP) in the human MOR gene.

Authors:  S Grösch; E Niederberger; J Lötsch; C Skarke; G Geisslinger
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

3.  Accelerated kindling development in mu-opioid receptor deficient mice.

Authors:  G Grecksch; A Becker; H Schroeder; J Kraus; H Loh; V Höllt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-12       Impact factor: 3.000

4.  Phenotypic concordance in 70 families with IGE-implications for genetic studies of epilepsy.

Authors:  Peter Kinirons; Daniel Rabinowitz; Micheline Gravel; James Long; Melodie Winawer; Geneviève Sénéchal; Ruth Ottman; Patrick Cossette
Journal:  Epilepsy Res       Date:  2008-08-23       Impact factor: 3.045

5.  The opioid antagonist naltrexone decreases seizure-like activity in genetic and chemically induced epilepsy models.

Authors:  Morgan L Sturgeon; Rachel Langton; Shaunik Sharma; Robert A Cornell; Joseph Glykys; Alexander G Bassuk
Journal:  Epilepsia Open       Date:  2021-06-09

Review 6.  Various pharmacogenetic aspects of antiepileptic drug therapy: a review.

Authors:  Michael W Mann; Gerard Pons
Journal:  CNS Drugs       Date:  2007       Impact factor: 6.497

Review 7.  Genetic Landscape of Common Epilepsies: Advancing towards Precision in Treatment.

Authors:  Sarita Thakran; Debleena Guin; Pooja Singh; Priyanka Singh; Samiksha Kukal; Chitra Rawat; Saroj Yadav; Suman S Kushwaha; Achal K Srivastava; Yasha Hasija; Luciano Saso; Srinivasan Ramachandran; Ritushree Kukreti
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.